Neal Flomenberg - 04 Mar 2025 Form 4 Insider Report for Tevogen Bio Holdings Inc. (TVGN)

Role
Chief Scientific Officer, Global R&D Lead
Signature
/s/ Kirti Desai, Attorney-in-Fact
Issuer symbol
TVGN
Transactions as of
04 Mar 2025
Net transactions value
-$250,006
Form type
4
Filing time
06 Mar 2025, 21:41:49 UTC
Previous filing
18 Oct 2024
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVGN Common Stock Sale $18,738 -14,639 -0.34% $1.28 4,239,663 04 Mar 2025 Direct F1, F2, F3
transaction TVGN Common Stock Sale $133,897 -110,659 -2.6% $1.21 4,129,004 05 Mar 2025 Direct F1, F2, F4
transaction TVGN Common Stock Sale $97,371 -88,519 -2.1% $1.10 4,040,485 06 Mar 2025 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4.
F3 These shares were sold in multiple transactions at prices ranging from $1.27 to $1.32, inclusive.
F4 These shares were sold in multiple transactions at prices ranging from $1.16 to $1.29, inclusive.
F5 These shares were sold in multiple transactions at prices ranging from $1.06 to $1.19, inclusive.

Remarks:

Chief Scientific Officer, Global R&D Lead